普埃拉林:一种肝脏保护药物,从长椅到床边
Yi-Xiang He1,2, Meng-Nan Liu2, Hao Wu2
1The Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Treatment of Digestive System Diseases of Luzhou City, Affiliated Traditional Medicine Hospital of Southwest Medical University, Luzhou, 646000, China.
Chinese medicine
|October 8, 2024
概括
来自Pueraria植物的Puerarin显示出治疗脂肪肝和肝癌等肝脏疾病的前景. 它的治疗潜力通过新的药物递送系统得到增强,尽管最初的生物可用性存在挑战.
科学领域:
- 药理学 药理学是指药理学的学科.
- 肝病学 肝病学是一种肝病学.
- 自然产品化学 自然产品化学
背景情况:
- 普埃拉里亚是一种传统的中国药用植物.
- 普埃拉林是主要活性化合物,具有多种药理性质.
- 普埃拉林对各种肝脏疾病表现出显著的肝保护作用.
研究的目的:
- 为了探索puerarin对肝脏疾病的药理作用.
- 调查皮亚林肝脏保护作用背后的机制.
- 评估puerarin作为治疗肝脏疾病的治疗剂的潜力.
主要方法:
- 对 puerarin 的药理学研究的审查.
- 分析包括炎症,氧化应激,脂质代谢,亡和自等机制.
- 检查药物动力学数据和药物输送系统的改进.
- 讨论临床试验结果和安全性概况.
主要成果:
- 普埃拉林对与代谢功能障碍相关的脂肪性肝病,与酒精有关的肝病和肝癌具有保护作用.
- 关键的机制包括对炎症因子的调节,氧化应激,脂质代谢,亡和自.
- 由于溶解性差,低生物利用率可以通过先进的药物输送系统来克服.
- 普埃拉林在临床前和临床研究中显示出低毒性和高安全性.
结论:
- 普埃拉林对各种肝脏疾病具有显著的治疗潜力.
- 它的有效性得到了多种药理机制和有利的安全性概况的支持.
- 进一步开发,特别是通过增强的输送系统,可以将 puerarin 确立为肝脏疾病的有价值的治疗选择.
相关概念视频
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
414
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
414
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
360
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
360
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
274
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
274
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
387
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
387